KR101747507B1 - 마이코플라즈마 하이요뉴모니아 백신 - Google Patents

마이코플라즈마 하이요뉴모니아 백신 Download PDF

Info

Publication number
KR101747507B1
KR101747507B1 KR1020147030860A KR20147030860A KR101747507B1 KR 101747507 B1 KR101747507 B1 KR 101747507B1 KR 1020147030860 A KR1020147030860 A KR 1020147030860A KR 20147030860 A KR20147030860 A KR 20147030860A KR 101747507 B1 KR101747507 B1 KR 101747507B1
Authority
KR
South Korea
Prior art keywords
mycoplasma
antigen
lys
leu
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147030860A
Other languages
English (en)
Korean (ko)
Other versions
KR20150003257A (ko
Inventor
제프리 이 갈빈
그레고리 피 니첼
존 케이트 가렛
제임스 알 세컨드 쿨라윅
트레이시 엘 릭커
메간 마리 스무처
Original Assignee
조에티스 서비시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48087777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101747507(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 조에티스 서비시즈 엘엘씨 filed Critical 조에티스 서비시즈 엘엘씨
Publication of KR20150003257A publication Critical patent/KR20150003257A/ko
Application granted granted Critical
Publication of KR101747507B1 publication Critical patent/KR101747507B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020147030860A 2012-04-04 2013-04-03 마이코플라즈마 하이요뉴모니아 백신 Active KR101747507B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261620165P 2012-04-04 2012-04-04
US61/620,165 2012-04-04
PCT/US2013/035083 WO2013152081A1 (en) 2012-04-04 2013-04-03 Mycoplasma hyopneumoniae vaccine

Publications (2)

Publication Number Publication Date
KR20150003257A KR20150003257A (ko) 2015-01-08
KR101747507B1 true KR101747507B1 (ko) 2017-06-14

Family

ID=48087777

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030860A Active KR101747507B1 (ko) 2012-04-04 2013-04-03 마이코플라즈마 하이요뉴모니아 백신

Country Status (31)

Country Link
US (5) US9120859B2 (https=)
EP (2) EP4039271A1 (https=)
JP (1) JP6271502B2 (https=)
KR (1) KR101747507B1 (https=)
CN (1) CN104271154B (https=)
AR (1) AR090611A1 (https=)
AU (1) AU2013243535C1 (https=)
BR (1) BR112014024533B1 (https=)
CA (1) CA2869603C (https=)
CL (1) CL2014002674A1 (https=)
CO (1) CO7160026A2 (https=)
CR (1) CR20140436A (https=)
CY (1) CY1124982T1 (https=)
DK (1) DK2833908T3 (https=)
ES (1) ES2905302T3 (https=)
GT (1) GT201400210A (https=)
HR (2) HRP20220175T1 (https=)
HU (1) HUE058321T2 (https=)
LT (1) LT2833908T (https=)
MX (2) MX336504B (https=)
MY (1) MY166792A (https=)
NI (1) NI201400117A (https=)
PH (1) PH12014502250A1 (https=)
PL (1) PL2833908T3 (https=)
PT (1) PT2833908T (https=)
RS (1) RS62881B1 (https=)
RU (1) RU2644254C2 (https=)
SI (1) SI2833908T1 (https=)
TW (1) TWI602575B (https=)
UA (1) UA114502C2 (https=)
WO (1) WO2013152081A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
AU2013370982C9 (en) * 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
US9649370B2 (en) 2013-05-08 2017-05-16 Protatek International, Inc. Vaccine for PCV2 and mycoplasma
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
BR112016010427B1 (pt) * 2013-11-21 2020-06-02 Agricultural Technology Research Institute Composição para prevenir infecção por mycoplasma spp., vetor de expressão, e método para prepararantígeno solúvel
US20150351428A1 (en) * 2014-06-04 2015-12-10 Animal Science Products, Inc. Methods and compositions for orally dosing postnatal swine
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
CN104324370B (zh) * 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
MX2018008415A (es) * 2016-01-07 2018-12-10 Univ Gent Cepas de vacuna de brachyspira hyodysenteriae.
US10953084B2 (en) * 2016-03-23 2021-03-23 Intervet Inc. Combination vaccine against PCV2 and PRRS virus infection comprising albumin
CN106497850B (zh) * 2016-12-20 2019-10-29 天津瑞普生物技术股份有限公司 一种纯化猪肺炎支原体的方法
ES2906854T3 (es) 2016-12-23 2022-04-20 Intervet Int Bv Vacuna combinada para cerdos
JP7510874B2 (ja) * 2017-12-22 2024-07-04 ヒプラ シエンティフィック エセ．エレ．ウ． マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
JP2022536410A (ja) * 2019-06-10 2022-08-16 エランコ・ユーエス・インコーポレイテッド Ｍｙｃｏｐｌａｓｍａ培地製剤
WO2021018806A1 (en) * 2019-07-26 2021-02-04 Ceva Sante Animale Igg-depleted porcine serum and the uses thereof
EP4185321A2 (en) * 2020-07-24 2023-05-31 Boehringer Ingelheim Animal Health USA Inc. Combination porcine vaccine
KR20220168099A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168100A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168098A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168101A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168097A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168102A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
CN114134098A (zh) * 2021-12-15 2022-03-04 成都史纪生物制药有限公司 一种猪肺炎支原体的灭活方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
WO1987005738A1 (fr) 1986-03-13 1987-09-24 Zahnradfabrik Friedrichshafen Ag Systeme pour irradier des liquides au moyen de faisceaux radioactifs
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
DE3855807T2 (de) 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JP3128133B2 (ja) 1991-06-06 2001-01-29 スティッチティング セントラール ディールゲネースクンディグ インスティトゥート 豚の奇病の原因体であるレリスタドエイジェント、それを含むワクチン組成物、豚の奇病の診断キット及び診断方法
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
DK0669971T3 (da) 1991-11-15 2003-04-22 Pfizer Fremgangsmåde til fremstilling af Gram-negative bakterielle vacciner
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
PT968722E (pt) 1994-05-10 2007-09-06 Wyeth Corp Vacina viva melhorada contra brsv.
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
AU1535299A (en) 1997-11-26 1999-06-15 Iowa State University Research Foundation Inc. Recombinant (mycoplasma hyopneumoniae) vaccine
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
CA2290220C (en) 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
CN1612749A (zh) * 2001-07-02 2005-05-04 辉瑞产品公司 用于减弱牲畜体内牛支原体肺炎的猪肺炎支原体疫苗和方法
EP2027873B8 (en) 2001-07-02 2015-11-11 Zoetis Services LLC One dose vaccination with mycoplasma hyopneumoniae
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EP1546357B1 (en) 2002-06-28 2013-08-07 Iowa State University Research Foundation, Inc. Immunogenic mycoplasma hyopneumoniae polypeptides
SI1651265T1 (sl) * 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
US8449989B2 (en) 2003-10-17 2013-05-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
RU2007130801A (ru) 2005-01-13 2009-02-20 Берингер Ингельхайм Ветмедика Гмбх (De) Улучшенные вакцины против репродуктивно-респираторного синдрома свиней (prrs)
ES2425228T3 (es) * 2005-09-09 2013-10-14 Intervet International B.V. Vacuna contra el PCV-2
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
EP3868400A1 (en) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
MX2008012972A (es) 2006-04-10 2009-01-16 Intervet Int Bv Vacuna contra sindrome respiratorio reproductivo porcino atenuado vivo de micoplasma.
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
EP2217271B1 (en) 2007-11-06 2016-05-04 Zoetis Services LLC Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
KR101320192B1 (ko) 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
WO2011141443A1 (en) 2010-05-11 2011-11-17 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
BR112013004594B1 (pt) * 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
BR112014022067B1 (pt) 2012-03-07 2022-05-31 Ceva Sante Animale Composição compreendendo antígeno e lipopolissacarídeo
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
KR102012109B1 (ko) * 2012-05-17 2019-08-19 조에티스 엘엘씨 이유 전 돼지 생식기 호흡기 증후군(prrs) 바이러스에 대한 효과적인 백신접종

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aust Vet J, Vol 75, Pages 504-511(1997)*

Also Published As

Publication number Publication date
CY1124982T1 (el) 2023-01-05
RU2014140107A (ru) 2016-05-27
US20170209560A1 (en) 2017-07-27
US10668139B2 (en) 2020-06-02
RS62881B1 (sr) 2022-03-31
EP4039271A1 (en) 2022-08-10
NI201400117A (es) 2015-03-05
CR20140436A (es) 2014-11-12
RU2644254C2 (ru) 2018-02-08
UA114502C2 (uk) 2017-06-26
AR090611A1 (es) 2014-11-26
CO7160026A2 (es) 2015-01-15
GT201400210A (es) 2015-06-02
MX336504B (es) 2016-01-21
TW201345550A (zh) 2013-11-16
JP6271502B2 (ja) 2018-01-31
LT2833908T (lt) 2022-02-25
WO2013152081A1 (en) 2013-10-10
HRP20140957A2 (hr) 2015-02-27
BR112014024533B1 (pt) 2021-06-01
EP2833908B1 (en) 2022-01-05
CN104271154B (zh) 2018-09-04
CA2869603C (en) 2018-06-12
PT2833908T (pt) 2022-02-17
DK2833908T3 (da) 2022-02-07
MX2014012014A (es) 2014-11-10
PH12014502250B1 (en) 2014-12-15
PL2833908T3 (pl) 2022-03-21
US10206991B2 (en) 2019-02-19
US20130266601A1 (en) 2013-10-10
US9120859B2 (en) 2015-09-01
HK1207284A1 (en) 2016-01-29
US9650600B2 (en) 2017-05-16
CN104271154A (zh) 2015-01-07
HRP20220175T1 (hr) 2022-04-29
CL2014002674A1 (es) 2014-12-12
MX354756B (es) 2018-03-20
TWI602575B (zh) 2017-10-21
US20150284677A1 (en) 2015-10-08
SI2833908T1 (sl) 2022-04-29
JP2015512448A (ja) 2015-04-27
PH12014502250A1 (en) 2014-12-15
KR20150003257A (ko) 2015-01-08
US11141472B2 (en) 2021-10-12
AU2013243535C1 (en) 2018-03-01
AU2013243535A1 (en) 2014-10-09
CA2869603A1 (en) 2013-10-10
US20190134176A1 (en) 2019-05-09
BR112014024533A2 (pt) 2017-08-08
ES2905302T3 (es) 2022-04-07
US20200330577A1 (en) 2020-10-22
MY166792A (en) 2018-07-23
EP2833908A1 (en) 2015-02-11
HUE058321T2 (hu) 2022-07-28
AU2013243535B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
KR101747507B1 (ko) 마이코플라즈마 하이요뉴모니아 백신
KR101808903B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아/prrs 조합 백신
KR102003620B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아 조합 백신
HK40072009A (en) Mycoplasma hyopneumoniae vaccine
CN104271153B (zh) Pcv/猪肺炎支原体/prrs组合疫苗
HK40010886A (en) Pcv/mycoplasma hyopneumoniae/prrs combination vaccine
HK40010885A (en) Pcv/mycoplasma hyopneumoniae combination vaccine
HK1206609B (en) Pcv/mycoplasma hyopneumoniae combination vaccine

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9